Search - tctmd.com

Displaying 461 - 480 of 1240

Sort: Relevancy | Date

News Daily News

Patients With A-fib and Cancer May Benefit From Visiting With a Cardiologist Early On

Todd Neale

October 10, 2018

News Daily News

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

Todd Neale

October 09, 2018

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

Caitlin E. Cox

October 04, 2018

News Daily News

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Todd Neale

October 03, 2018

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation TCT 2018

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

Presenter: George D. Dangas, Giuseppe Tarantini, Steven R. Bailey, Giovanni Esposito, Juan F. Granada, Roxana Mehran, Francesco Saia

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

Case Presentation: Chronic Oral Anticoagulant and Antiplatelet Management Decisions

Presenter: Walter Desmet, Guy J. Friedrich, Kurt Huber, Eduard Margetic, Oleg Polonetsky

September 22, 2018

News Conference News TCT 2018

Novel LAA Closure Device Shows Promise in Early Experience

L.A. McKeown

September 22, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Daily News

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

Todd Neale

September 13, 2018

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Todd Neale

August 27, 2018

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Todd Neale

August 26, 2018

News Conference News ESC 2018

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

Michael O'Riordan

August 25, 2018

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Todd Neale

August 17, 2018

Advertisement

Patients With A-fib and Cancer May Benefit From Visiting With a Cardiologist Early On

GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

Stay Away From Warfarin-Based Triple Therapy in Patients With A-fib and CAD, Study Affirms

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Consensus: Considerations In The High Bleeding Risk Patient Requiring PCI And Oral Anticoagulant Therapy

Case #1 Introduction: A High Bleeding Risk Patient With Afib And ACS Requiring PCI And Oral Anticoagulant Therapy

High Mortality but Durable Results With Valve-in-Valve TAVR

Case Presentation: Chronic Oral Anticoagulant and Antiplatelet Management Decisions

Novel LAA Closure Device Shows Promise in Early Experience

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Good INR Control on Warfarin Doesn’t Necessarily Predict Future Success, Outcomes

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content